Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06399653 · ClinicalTrials.gov registry record · NA

Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder

A NA study of Alcohol Use Disorder, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06399653: Recruiting NA study of Alcohol Use Disorder, sponsored by VA Office of Research and Development.

NCT06399653 is a NA study of Alcohol Use Disorder that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 80 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06399653, a NA study of Alcohol Use Disorder, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes functional impairments and decreased quality of life. Current AUD treatments show limited effectiveness in reducing withdrawal-related psychological and physical distress, which drives the urge to drink to relieve these symptoms. The investigators propose the vagus nerve, which is the primary nerve of the "rest and digest" branch of the autonomic nervous system via its bidirectional connections between the brain and the body, as a novel treatment target for AUD. The goal of this study is to assess treatment efficacy and mechanism of action. Noninvasive neuromodulation technologies offer the possibility for innovative, low risk treatments to support the rehabilitation and community reintegration of Veterans with AUD.

Primary Outcome

The HAM-A is a 14-item scale that assesses the presence and severity of psychological distress and negative emotional states. Completion takes 10 minutes. This instrument is widely used in clinical trials and alcohol studies and is sensitive to both nVNS and AUD treatment. Items are rated on a scale ranging from 0 (not present) to 4 (very severe).

Conditions Studied

Interventions

  • DEVICE Cervical transcutaneous vagus nerve stimulation (active comparator)
  • DEVICE Cervical transcutaneous vagus nerve stimulation (sham comparator)

Study Locations (1)

California

  • VA San Diego Healthcare System, San Diego, CA - San Diego

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-01-01
Est. Completion 2029-08-31
Phase NA
VA Office of Research and Development

1,668 total trials

What NCT06399653 shows while recruiting

NCT06399653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cervical transcutaneous vagus nerve stimulation (active comparator) is the first listed.

NCT06399653 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06399653 about?

NCT06399653 is a clinical study titled "Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder". Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes functional impairments and decreased quality of life. Current AUD treatments show limited effectiveness in reducing withdrawal-related psychological and physical distress, which drives the urge to drink to relieve the...

What is the current status of trial NCT06399653?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-01-01. Estimated completion is 2029-08-31.

What conditions does trial NCT06399653 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT06399653?

The interventions under investigation include: Cervical transcutaneous vagus nerve stimulation (active comparator) (DEVICE), Cervical transcutaneous vagus nerve stimulation (sham comparator) (DEVICE).

Who is sponsoring clinical trial NCT06399653?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06399653 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06399653's enrollment target sits among peer trials

80 100th of 184 higher than 79 of 184 other Alcohol Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06399653, the US trial registry maintained by the National Library of Medicine. NCT06399653 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.